Cytokinetics complied with Nasdaq Listing Rule 5635(c)(4) regarding inducement grants on August 20, 2025.
3 reports, 1 independent
Updated Jul 1
Gone quiet
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cytokinetics complied with Nasdaq Listing Rule 5635(c)(4) regarding inducement grants on August 20, 2025.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Cytokinetics
company in South San Francisco, United States
-
Securities and Exchange Commission
government agency of the Philippines
Related events
- BioLineRx Ltd. is utilizing the Nasdaq stock exchange for a registered direct offering, filing with the SEC.
- The Ensign Group, Inc. filed required documents with the SEC and was listed on the Nasdaq stock exchange.
- Jaguar Health, Inc. filed a proxy statement with the SEC and is seeking compliance with Nasdaq listing standards.
Coverage
Newest first; wire copies grouped- GlobeNewswireCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced
- GlobeNewswireCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) SOUTH SAN FRANCISCO, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced